| antibody–drug conjugate |
| trastuzumab deruxtecan | trastuzumab emtansine |
| la/mBC - HER2 positive | | |
| la/mBC - HER2 positive - (neo)adjuvant (NA) | | |
| la/mBC - HER2 positive - 1st Line (L1) 5 | | |
| la/mBC - HER2 positive - 2nd Line (L2) 13 | | |
Comparator:
vs trastuzumab emtansine; vs lapatinib plus capecitabine;
Risk of bias:
low;
some concerns;
high;
NA;